---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-042812"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2026-02-09T23:59:59+00:00"
generated_at: "2026-05-16T03:50:16.102592+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Enanta Q1 FY2026 net loss $11.9M ($0.42/sh); pipeline advances with zelicapavir and new immunology programs

## Summary
- Revenue of $18.6M from AbbVie royalties, up 9% vs $17.0M YoY; net loss narrowed to $11.9M from $22.3M.
- Cash & securities $241.9M; runway expected into fiscal 2029.
- Zelicapavir Phase 2b RSVHR showed 6.7-day improvement in symptom resolution for high-risk adults; Phase 3 enabling activities ongoing.
- New MRGPRX2 immunology program introduced; development candidate selection expected in 2H 2026.
- EDP-978 (oral KIT) IND on track for Q1 2026; EPS-3903 (oral STAT6) IND targeting 2H 2026.

## SEC filing metadata
- accession: 0001193125-26-042812
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2026-02-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000119312526042812/0001193125-26-042812-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000119312526042812/enta-20260209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-042812
- JSON: https://secwatch.observer/filing/0001193125-26-042812.json
- Plain text: https://secwatch.observer/filing/0001193125-26-042812.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.